Management of cancer anemia

Journal of Chemotherapy

Volumn 16, Issue SUPPL. 4, 2004, Pages 112-116

  Grossi, A ^a,b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b AOUC   (Italy)

Author keywords

Anemia; Cancer; Recombinant human erythropoietin

Indexed keywords

ANTIBODY; CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR; ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

ANEMIA; BLOOD TRANSFUSION; CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CENTRAL NERVOUS SYSTEM; CLINICAL TRIAL; COGNITION; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; KIDNEY FAILURE; MYELODYSPLASTIC SYNDROME; OUTCOMES RESEARCH; PROGNOSIS; QUALITY OF LIFE; SIDE EFFECT; TUMOR GROWTH;

EID: 11244256619     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2004.16.supplement-1.112     Document Type: Conference Paper

References (23)

1. Skillings JR, Roger-Melamed I, Nabholtz JM, et al. An epidemiological review of anaemia in cancer chemotherapy in Canada. Eur J Cancer 1995; 31a Suppl 5: abstr.
2. Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34, Suppl 2: 13-19.
3. Beguin Y, Yerna M, Loo M, Weber M, Fillet G. Erythropoiesis in multiple myeloma: defective red cells production due to inappropriate erythropoietin production. Br J Haematol 1992; 82: 648-653.
4. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes. A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 1998; 103(4): 1070-1074.
5. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998; 92(1): 68-75.
6. Terpos E, Mougiou A, Kouraklis A, et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol. 2002; 118(1): 174-180.
7. Rizzo JD, Lichtin AE, Woolf SH, et al. Us of erythropoietin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002; 20(19): 4083-4107.
8. Alessandrino EP, Amadori S, Barosi G, et al. Evidence-and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002; 87(12): 1286-1306.
9. Gabrilove JL, Cleeland CS, Livingstone RB, Sarokan B, Winer E, Einhorn LH. Clinical evaluation of once-weekly dosing of epoetin alpha in chemotherapy patients: improvements in hemoglobina and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001; 19: 2875-2882.
10. Egrie JC, Browne JK Development and characterization of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84 Suppl. 1: 3-10.
11. Smith RE Jr, Jaiyesimi IA, Meza LA, et al. Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer. Br J Cancer. 2001; 84, Suppl. 1: 24-30.
12. Glaspy JA, Jadeja JS, Justice G, et al. Darbepoetin alpha given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer 2002; 87(3): 268-276.
13. Glaspy J, Jadeja J, Justice G et al. Randomized, active controlled, phase 1/2, dose escalation study of NESP administered weekly and every 2 weeks in patients with solid tumors. Proc Am Soc Clin Oncol 2001; 20: 387a (abstr).
14. Hedenus M, Adriansson M, San Miguel J, et al. Efficacy and safety of darbepoetin alpha in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003; 122(3): 394-403.
15. Kotasek D, Steger G, Faught W, et al. Darbepoetin alpha administered every 3 weeks alleviates anaemia in patients with solid tumours receiving chemotherapy; results of a double-blind, placebo-controlled, randomised study. Eur J Cancer 2003; 39(14): 2026-2034.
16. Dougherty FC, Reigner B, Jordan P, Pannier A. CERA (continuous erythropoiesis receptor activator) demonstrates dose-dependent activity and is well tolerated in Phase I multiple ascending dose studies. Blood 2003; 102(11): 204a (abs).
17. Glaspy J, Bukowsky R, Steinberg D, et al. Impact of therapy with epoetin alpha on clinical outcomes in patients with non myeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997; 15: 1218-1234.
18. Leyland-Jones B, BEST Investigators and Study Group. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4(8): 459-460.
19. Henke M, Laszig R, Rube C, et al. Erythropoietin to treat head and neck cancer patients with anemia undergoing radiotherapy: randomised, double-blind, placebo controlled trial. Lancet 2003; 362: 1255-1260.
20. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B. Epoetin alpha study group. Effects of epoetin alpha on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001; 19 (11): 2865-2874.
21. Leyland-Jones B, O'Shaughnessy JA. Erythropoietin as a critical component of breast cancer therapy: survival, synergistic, and cognitive applications. Semin Oncol. 2003; 30, Suppl 16: 174-184.
22. Olsen NV. Central Nervous System frontiers for use of Erythropoietin C I D 2003; 37, Suppl 4: 323-330.
23. Casadevall N. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin. Nephrol Dial Transplant. 2003; 18, Suppl 8: 37-41.